Viridian Therapeutics, Inc.
VRDN
$18.95
$0.935.16%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -100.74M | -86.91M | -79.73M | -76.69M | -64.99M |
Total Depreciation and Amortization | 113.00K | 117.00K | 23.00K | 930.00K | 142.00K |
Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
Total Other Non-Cash Items | 9.38M | 8.00M | 5.91M | 5.09M | 7.67M |
Change in Net Operating Assets | 15.87M | -13.86M | 460.00K | 2.97M | 11.13M |
Cash from Operations | -75.37M | -92.65M | -73.33M | -67.71M | -46.06M |
Capital Expenditure | -42.00K | -86.00K | -114.00K | -293.00K | -104.00K |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | 75.76M | 100.15M | -62.80M | -84.37M | 62.08M |
Cash from Investing | 75.72M | 100.06M | -62.92M | -84.67M | 61.98M |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | -- | -- | -- | -- | -- |
Issuance of Common Stock | 764.00K | 9.42M | 36.83M | 235.18M | 210.00K |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | 0.00 | 25.00M | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 0.00 | -207.00K | -1.31M | -15.15M | -102.00K |
Cash from Financing | 764.00K | 9.21M | 35.52M | 245.02M | 108.00K |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 1.11M | 16.62M | -100.72M | 92.65M | 16.03M |